Piper Jaffray analyst Joseph Catanzaro says he spoke with a KOL as the commercial launch of Catalyst Pharmaceuticals' Firdapse gets underway, who believed that all 12 of his LEMS patients, previously part of the Jacobus IND, have transitioned to Firdapse through the Catalyst Pathways program. Ultimately, he believed that the clinical data package supporting the approval of Firdapse would be difficult for both physicians and insurers to ignore, and expected broad payer coverage over time, the analyst notes. Catanzaro believes this KOL's experience speaks positively to the work Catalyst has done to identify LEMS patients, transition them to Firdapse and obtain payer coverage. He reiterates an Overweight rating and $7.50 price target on Catalyst Pharmaceuticals' shares.